Enhanced dissolution of valsartan-vanillin binary co-amorphous system loaded in mesoporous silica particles

References

• Ahsan, M.N., and Verma, P.R.P., 2018. Enhancement of in vitro dissolution and pharmacodynamic potential of olanzapine using solid SNEDDS. Journal of pharmaceutical investigation, 48 (3), 269–278.
   Google Scholar
• Allesø, M., et al., 2009. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen–cimetidine mixtures prepared by mechanical activation. Journal of controlled release, 136 (1), 45–53.
   PubMed Web of Science ®Google Scholar
• Beg, S., et al., 2012. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech, 13 (4), 1416–1427.
   PubMed Web of Science ®Google Scholar
• Bi, Y., et al., 2016. Facile large-scale preparation of mesoporous silica microspheres with the assistance of sucrose and their drug loading and releasing properties. International journal of pharmaceutics, 500 (1–2), 77–84.
   PubMed Web of Science ®Google Scholar
• Bi, Y., et al., 2017. The binary system of ibuprofen-nicotinamide under nanoscale confinement: from cocrystal to coamorphous state. Journal of pharmaceutical sciences, 106 (10), 3150–3155.
   PubMed Web of Science ®Google Scholar
• Cappello, B., et al., 2006. Improvement of solubility and stability of valsartan by hydroxypropyl-boldbeta-cyclodextrin. Journal of inclusion phenomena and macrocyclic chemistry, 54 (3–4), 289.
   Web of Science ®Google Scholar
• Chavan, R.B., et al., 2016. Coamorphous systems: a product development perspective. International journal of pharmaceutics, 515 (1–2), 403–415.
   PubMed Web of Science ®Google Scholar
• Chavda, H., Patel, C., and Anand, I., 2010. Biopharmaceutics classification system. Systematic reviews in pharmacy, 1 (1), 62.
   Google Scholar
• Clas, S.-D., Dalton, C.R., and Hancock, B.C., 1999. Differential scanning calorimetry: applications in drug development. Pharmaceutical science & technology today, 2, 311–320.
   PubMedGoogle Scholar
• Dash, S., et al., 2010. Kinetic modeling on drug release from controlled drug delivery systems. Acta poloniae pharmaceutica, 67 (3), 217–223.
   PubMed Web of Science ®Google Scholar
• Dengale, S.J., et al., 2016. Recent advances in co-amorphous drug formulations. Advanced drug delivery reviews, 100, 116–125.
   PubMed Web of Science ®Google Scholar
• Dengale, S.J., et al., 2014. Preparation and characterization of co-amorphous Ritonavir–Indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions. European journal of pharmaceutical sciences, 62, 57–64.
   PubMed Web of Science ®Google Scholar
• Dixit, A.R., Rajput, S.J., and Patel, S.G., 2010. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech, 11 (1), 314–321.
   PubMed Web of Science ®Google Scholar
• Doadrio, A., et al., 2004. Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. Journal of controlled release, 97 (1), 125–132.
   PubMed Web of Science ®Google Scholar
• Flesch, G., Müller, P., and Lloyd, P., 1997. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. European journal of clinical pharmacology, 52 (2), 115–120.
   PubMed Web of Science ®Google Scholar
• Fu, C., et al., 2013. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials, 34 (10), 2565–2575.
   PubMed Web of Science ®Google Scholar
• Gala, U., Pham, H., and Chauhan, H., 2013. Pharmaceutical applications of eutectic mixtures. Journal of developing drugs, 2, 1–2.
   Google Scholar
• Gao, Y., et al., 2013. Coamorphous repaglinide–saccharin with enhanced dissolution. International journal of pharmaceutics, 450 (1–2), 290–295.
   PubMed Web of Science ®Google Scholar
• Giunchedi, P., et al., 2002. Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. European journal of pharmaceutics and biopharmaceutics, 53 (2), 233–239.
   PubMed Web of Science ®Google Scholar
• Hancock, B.C., and Parks, M., 2000. What is the true solubility advantage for amorphous pharmaceuticals?. Pharmaceutical research, 17 (4), 397–404.
   PubMed Web of Science ®Google Scholar
• Heng, D., et al., 2008. What is a suitable dissolution method for drug nanoparticles? Pharmaceutical research, 25 (7), 1696–1701.
   PubMed Web of Science ®Google Scholar
• Hong, S.H., and Choi, Y., 2018. Mesoporous silica-based nanoplatforms for the delivery of photodynamic therapy agents. Journal of pharmaceutical investigation, 48 (1), 3–17.
   PubMedGoogle Scholar
• Huang, Y., et al., 2017. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan. Pharmaceutical development and technology, 22 (1), 69–76.
   PubMed Web of Science ®Google Scholar
• Kalam, M.A., et al., 2007. Release kinetics of modified pharmaceutical dosage forms: a review. Continental journal of pharmaceutical sciences, 1, 30–35.
   Google Scholar
• Kamaraj, S., et al., 2018. Curcumin drug delivery by vanillin-chitosan coated with calcium ferrite hybrid nanoparticles as carrier. European journal of pharmaceutical sciences, 116, 48–60.
   PubMed Web of Science ®Google Scholar
• Karagianni, A., Kachrimanis, K., and Nikolakakis, I., 2018. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: Composition, preparation, characterization and formulations for oral delivery. Pharmaceutics, 10 (3), 98.
   PubMed Web of Science ®Google Scholar
• Kaza, R., Raju, Y.P., and Nagaraju, R., 2013. Dissolution enhancement of valsartan using natural polymers by solid dispersion technique. Der pharmacia lettre, 5, 126–134.
   Google Scholar
• Laitinen, R., et al., 2014. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Molecular pharmaceutics, 11 (7), 2381–2389.
   PubMed Web of Science ®Google Scholar
• Latif, F., et al., 2001. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. Journal of cardiac failure, 7 (3), 265–268.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 2009. Solubility of valsartan in different organic solvents and ethanol + water binary mixtures from (278.15 to 313.15) K. Journal of chemical & engineering data, 54, 986–988.
   Web of Science ®Google Scholar
• Löbmann, K., et al., 2013. Amino acids as co-amorphous stabilizers for poorly water soluble drugs–Part 1: preparation, stability and dissolution enhancement. European journal of pharmaceutics and biopharmaceutics, 85 (3), 873–881.
   PubMed Web of Science ®Google Scholar
• Löbmann, K., et al., 2011. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Molecular pharmaceutics, 8 (5), 1919–1928.
   PubMed Web of Science ®Google Scholar
• Lodagekar, A., et al., 2018. Role of valsartan as an antiplasticizer in development of therapeutically viable drug–drug coamorphous system. Crystal growth & design, 18, 1944–1950.
   Web of Science ®Google Scholar
• Markham, A., and Goa, K.L., 1997. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs, 54 (2), 299–311.
   PubMed Web of Science ®Google Scholar
• Müller, P., et al., 1997. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. European journal of clinical pharmacology, 52, 441–449.
   PubMed Web of Science ®Google Scholar
• Nekkanti, V., Wang, Z., and Betageri, G.V., 2016. Pharmacokinetic evaluation of improved oral bioavailability of valsartan: proliposomes versus self-nanoemulsifying drug delivery system. AAPS PharmSciTech, 17 (4), 851–862.
   PubMed Web of Science ®Google Scholar
• Newman, A., Reutzel-Edens, S.M., and Zografi, G., 2018. Coamorphous active pharmaceutical ingredient–small molecule mixtures: Considerations in the choice of coformers for enhancing dissolution and oral bioavailability. Journal of pharmaceutical sciences, 107 (1), 5–17.
   PubMed Web of Science ®Google Scholar
• Park, Y.J., et al., 2010. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Archives of pharmacal research, 33 (8), 1235–1240.
   PubMed Web of Science ®Google Scholar
• Peng, H., et al., 2010. Vanillin cross-linked chitosan microspheres for controlled release of resveratrol. Food chemistry, 121 (1), 23–28.
   Web of Science ®Google Scholar
• Poudel, B.K., et al., 2012. Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment. Chemical and pharmaceutical bulletin, 60 (11), 1409–1418.
   PubMed Web of Science ®Google Scholar
• Pradhan, R., et al., 2016. Preparation and characterization of spray-dried valsartan-loaded Eudragit® E PO solid dispersion microparticles. Asian journal of pharmaceutical sciences, 11 (6), 744–750.
   Web of Science ®Google Scholar
• Qian, K.K., and Bogner, R.H., 2012. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. Journal of pharmaceutical sciences, 101 (2), 444–463.
   PubMed Web of Science ®Google Scholar
• Riikonen, J., Xu, W., and Lehto, V.-P., 2018. Mesoporous systems for poorly soluble drugs–recent trends. International journal of pharmaceutics, 536 (1), 178–186.
   PubMed Web of Science ®Google Scholar
• Sadoun, O., Rezgui, F., and G'sell, C., 2018. Optimization of valsartan encapsulation in biodegradables polyesters using Box-Behnken design. Materials science and engineering: C, 90, 189–197.
   PubMed Web of Science ®Google Scholar
• Savolainen, M., et al., 2009. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. European journal of pharmaceutics and biopharmaceutics, 71 (1), 71–79.
   PubMed Web of Science ®Google Scholar
• Shayanfar, A., et al., 2013. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. Journal of pharmacy & pharmaceutical sciences, 16, 577–587.
   PubMed Web of Science ®Google Scholar
• Shayanfar, A., and Jouyban, A., 2013. Drug–drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide. Journal of pharmaceutical innovation, 8 (4), 218–228.
   Web of Science ®Google Scholar
• Singh, D., Bedi, N., and Tiwary, A.K., 2018. Enhancing solubility of poorly aqueous soluble drugs: critical appraisal of techniques. Journal of pharmaceutical investigation, 48 (5), 509–526.
   Google Scholar
• Vallet-Regí, M., et al., 2017. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules, 23 (1), 47.
   PubMed Web of Science ®Google Scholar
• Vallet‐Regí, M., Balas, F., and Arcos, D., 2007. Mesoporous materials for drug delivery. Angewandte chemie international edition, 46, 7548–7558.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2017. Coamorphous loratadine-citric acid system with enhanced physical stability and bioavailability. AAPS PharmSciTech, 18 (7), 2541–2550.
   PubMed Web of Science ®Google Scholar
• Xu, C., et al., 2018. Self-healing chitosan/vanillin hydrogels based on Schiff-base bond/hydrogen bond hybrid linkages. Polymer testing, 66, 155–163.
   Web of Science ®Google Scholar
• Yamamura, S., et al., 2000. Physicochemical properties of amorphous precipitates of cimetidine–indomethacin binary system. European journal of pharmaceutics and biopharmaceutics, 49 (3), 259–265.
   PubMed Web of Science ®Google Scholar
• Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Advanced drug delivery reviews, 48 (1), 27–42.
   PubMed Web of Science ®Google Scholar
• Zhou, D., et al., 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. Journal of pharmaceutical sciences, 91 (8), 1863–1872.
   PubMed Web of Science ®Google Scholar